摘要: Triple-negative breast cancer (TNBC) lacks the three most commonly targeted receptors in human cancer--the estrogen receptor (ER), progesterone (PR), and epidermal growth factor 2 (HER2)/neu--and it is associated with an aggressive natural history. More recently, TNBC has been further dissected into smaller, distinct subsets unique molecular alterations response to therapy. Large-scale genomic projects have yielded new knowledge about characteristics of TNBC, including similarities high-grade serous ovarian cancers, suggesting a possible coordinated treatment algorithm for these malignancies. Moreover, translation preclinical findings led clinical trials testing plethora targets pathways which will be reviewed here; include (EGFR), angiogenesis, DNA repair capacity, epigenetic regulation, androgen (AR) folate (FR) signaling, cell-cycle control, cell survival. Given complexity biology lack "traditional" therapeutic targets, advancement care women require true partnership between clinicians, translational investigators, basic scientists.
cancernetwork.com参考文章(60)
Nicholas Turner, Andrew Tutt, Alan Ashworth, Hallmarks of 'BRCAness' in sporadic cancers Nature Reviews Cancer. ,vol. 4, pp. 814- 819 ,(2004) , 10.1038/NRC1457
S. J. Isakoff, P. E. Goss, E. L. Mayer, T. A. Traina, L. A. Carey, K. Krag, H. S. Rugo, M. C. Liu, V. Stearns, S. E. Come, D. R. Borger, C. A. Quadrino, D. Finkelstein, J. E. Garber, P. D. Ryan, E. P. Winer, L. W. Ellisen, , TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal of Clinical Oncology. ,vol. 29, pp. 1025- 1025 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.1025
Maura N. Dickler, Melody A. Cobleigh, Kathy D. Miller, Pamela M. Klein, Eric P. Winer, Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Breast Cancer Research and Treatment. ,vol. 115, pp. 115- 121 ,(2009) , 10.1007/S10549-008-0055-9
Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew N. J. Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M. B. Martin, Stephen P. Jackson, Graeme C. M. Smith, Alan Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. ,vol. 434, pp. 917- 921 ,(2005) , 10.1038/NATURE03445
P N Munster, K T Thurn, S Thomas, P Raha, M Lacevic, A Miller, M Melisko, R Ismail-Khan, H Rugo, M Moasser, S E Minton, A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer British Journal of Cancer. ,vol. 104, pp. 1828- 1835 ,(2011) , 10.1038/BJC.2011.156
SJ Isakoff, B Overmoyer, NM Tung, RS Gelman, K Habin, J Qian, V Giranda, S Shepherd, JE Garber, LW Ellisen, EP Winer, PE Goss, P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. Cancer Research. ,vol. 71, ,(2011) , 10.1158/0008-5472.SABCS11-P3-16-05
Rachael Natrajan, Britta Weigelt, Alan Mackay, Felipe C. Geyer, Anita Grigoriadis, David S. P. Tan, Chris Jones, Christopher J. Lord, Radost Vatcheva, Socorro M. Rodriguez-Pinilla, Jose Palacios, Alan Ashworth, Jorge S. Reis-Filho, An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers Breast Cancer Research and Treatment. ,vol. 121, pp. 575- 589 ,(2010) , 10.1007/S10549-009-0501-3
Peter C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui-Roelvink, Charlie Gourley, Jacques De Greve, Jan Lubinski, Susan Shanley, Christina Messiou, Roger A'Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye, Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval Journal of Clinical Oncology. ,vol. 28, pp. 2512- 2519 ,(2010) , 10.1200/JCO.2009.26.9589
Helen E. Bryant, Niklas Schultz, Huw D. Thomas, Kayan M. Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J. Curtin, Thomas Helleday, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature. ,vol. 434, pp. 913- 917 ,(2005) , 10.1038/NATURE03443
Lucio Tentori, Grazia Graziani, Chemopotentiation by PARP inhibitors in cancer therapy Pharmacological Research. ,vol. 52, pp. 25- 33 ,(2005) , 10.1016/J.PHRS.2005.02.010